London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Going by the content of that disastrous AR, we will be lucky to make it till the end of the year. The only consolation we have is that Jim is excited about it......
I told you 2025 is the Year for success!
agree bignose.ive now finished reading it.frankly coundnt bear to read it all at once.clearly they are just being kept going by shareholder loans which they wont/can't carry on with for very long.there is absolutely no prospect of any meaningful (or even any) income for the foreseeable future.obviously the auditors insisted on the revised valuation of fortacin before they would sign off the accountts(well thats my opinion anyway ) and explains the termination of the live price feed on website.they cannot pay for it.my guess is they will struggle on till and of july/august to see if they can get RX to OTC approval but very probably they won't get it and then recordati will say no more and they will go into administration.possibly gibson could be replaced but who would take it on? that could only happen imo as part of some sort of RTO and although not entirely impossible is probably just wishful thinking.
Future growth.... how will that ever be achieved with JG at the helm? His incompetence as a businessman is now plainly clear to see, yet still ignored. Any future consolidated company will just suffer in the same way. I wouldn't be surprised if he is not given a rise and awarded a bonus in shares.
JM stated "The current strategy of the Group can be seen in the latest Company’s presentation" (March 2019):
• Vision to create a healthcare company serving the dynamic global healthcare market • Regent has the management and track record to build a strong healthcare portfolio,
• Regent has the management and track record to build a strong healthcare portfolio.
Which doesn't really tie in with "these conditions indicate that a material uncertainty exists
that may cast significant doubt on the Group’s ability to continue as a going concern"
yes bignose if he does do something with the listing we would all be diluted even more,but i suppose there would at least be the prospect of future growth which seems to have evaporated entirely here I'm afraid
completely agree bignose.yes interesting that no dialogue from gibson.i think there are three problems.first hardly anyone wants to buy the product second even if anyone did want to buy it they canot get it manufactured properly.third even if someone might want to buy it and they could actually get it produced the ceo has no understanding of the pharma market and authorisation procedures and is unable to progress in many areas where it might be sold.no way out of this imo.need to change direction and BOD if at all possible.probably not going to happen.if anyone wants to feel even worse have a look at EMMACs announcement today as a demonstration of competent progress.sorry to be so negative.gla in these very difficult times.
And just as a further reminder from the PLE March 2014 RNS:
In January 2014, a successful guidance meeting took place with the FDA in the USA to establish a defined pathway to secure regulatory approval to commercialise PSD502™ as a prescribed treatment for premature ejaculation in the USA. The agreed pathway will require supplementary clinical trials to be carried out to facilitate the completion of a new dossier for approval. We estimate that these trials will commence later this year and take approximately five months to complete at cost of approximately US$5 million. The process to establish the design and structure of the new clinical trials has been completed subject to final FDA approval. The Company aims to commence the trials later this year. Submission of the new dossier to the FDA is anticipated to be made during Q1 2016. Based on a maximum 10 month assessment period under the protocol defined by the Prescription Drug User Fee Act, a target launch of PSD502™ in the USA is anticipated to take place during the first part of 2017.
6 years ago this month ...WTF have they been up to ??? and since that time JG has been paid how much exactly.....
About 9 mill USD !!!
He may just do that, but at what cost to existing shareholders? We will all be lucky to get half of our investment back.....and that's not for another 2 or 3 years.
A completely disastrous report. (Notice no dialogue from the CEO). Nothing but lies lies and more lies.
Just as a reminder from the 18th July announcement:
"The Board is also pleased to report that the Phase II validation study of Fortacin™ in respect of the FDA approval process in the US is now estimated to complete by the end of 2019. On the assumption that the trial is sufficient to convince the FDA that the PEBEQ serves as an appropriate measure for support of a label claim, pivotal Phase III work could commence in Q1 of 2020, with NDA submission possible in the second half of 2020, giving a PDUFA date in 2021. These dates are the most recent guidance received and update all previous estimates on the FDA process set out by the Company in its announcements, annual and interim reports and investor presentations:"
And this was changed from the end of March 2020 date. They have no idea what they are doing or what they are writing.
And now all the delays associated with production issues.......... WTF. I thought these people were the so called experts.
I will be surprised if this does not fall to new lows tomorrow.... with an increased market cap to salary % for JG who deserves nothing.
so frustrating with the constant let downs and change of time frames
probably so dougie. the only thing i can think of which might get us out of this is if mellon doesn't want to lose the HK listing and uses it as a vehicle for some sort of RTO.where that would leave existing investors I've no idea but i cannot see it continuing like this for very long.
think we are at the end of the road here surely, more delays more problems
It is difficult to find words to describe this.....UGH!
it just gets worse and worse
and" rewarding" .you really couldn't make it up. speechless!
Read them and weep....or be happy...lol